Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by wildbird1on Dec 18, 2024 6:15pm
229 Views
Post# 36369181

RE:RE:JV with Merck's Keyteuda a bad idea...

RE:RE:JV with Merck's Keyteuda a bad idea...

Gojotv and Maxitrac  maybe $200 shares is way overkill.

Although it all depend on the market exposure.
If you take into account only bladder cancer, ok $200 shares is way overkill.

But as in this article on Theralase exposure...
Theralase adds cancer immunotherapy to potential revenue streams | 2024-06-18 | Investing News | Stockhouse

In this article it said, Bladder Cancer market is US$5 billion, plus Immunotherapy market US$125 billion, plus Chemotherapy market US$157 billion, plus Lung cancer market US$30 billion, you end up with TLT having an exposure to over a US$300 billion market.

With the possibility of having exposure to a US$300 billion market, maybe when TLT has the money to attack these market(could be sooner than we think), then a $100/$200 share is not out of reach.
For now we have to stay focus on bladder cancer, for the other future market, with money in the coffer,TLT will have a lot of big upside.

You also have to wonder if a Big Pharma when negotiating with TLT, will take into account this huge US$300 billion market exposure (that is a tough and expensive $$$ question?)?


Maxcitrac wrote: I like the $200.00 target price, Theralase will get there one day.

As for immunotherapy, TLT compound(Rutherrin) work with Immunotherapy as specified in this link.
2024-06-18 | Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically | TSXV:TLT | Press Release

And immunotherapy market is approximately US125 Billion a year, and Theralase will certainly one day grab a chunk of it.

gojotv! wrote: When business hounds try Science, crazy ideas abound. I'm reading here that some want to JV with Merck and "combo" Ruvidar with Keytruda...
The idea doesn't work on so many levels.
First, Keytruda is an immunotherapy, where Ruvidar is a targeted cancer killer.
Second, Keytruda's patent expires in a couple of years, before Ruvidar's usefulness in other cancer therapies can be fully developed.
Also, Keytruda has toxicities which Ruvidar aims to eliminate from oncology.
And most of all, Ruvidar is currently being tested in a "two treatment" protocol, which limits our results. In the real world, patients will be able to get Rividar until their cancer is destroyed - any time after the first treatment. Can you imagine how our "partial response" patients would do after 4 or 5 treatments? They'd be cancer-free, IMO.
So, enough with the crazy talk, let's aim for "Ruvidar - exclusive" treatment protocols, and a $200 share price.
And that is all.
Happy Holidays!





 

<< Previous
Bullboard Posts
Next >>